HF
SPRO icon

HRT Financial’s Spero Therapeutics SPRO Stock Holding History

HRT Financial’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,692
Closed -$15K – 3334
2024
Q4 		$15K Buy
+14,692
New +$17.5K ﹤0.01% 2247
2023
Q4 		– Sell
-18,627
Closed -$22K – 3032
2023
Q3 		$22K Buy
+18,627
New +$25.8K ﹤0.01% 2060
2022
Q2 		– Sell
-11,277
Closed -$98K – 3686
2022
Q1 		$98K Buy
+11,277
New +$116K ﹤0.01% 2663

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial's SPRO Position: Q1 2025 in Review

HRT Financial sold out of Spero Therapeutics (SPRO) in Q1 2025, closing a stake of 14,692 shares — an estimated $15K sold.

HRT Financial first reported a position in SPRO in Q1 2022 and held it in 3 quarters. The position peaked at $98K in Q1 2022. 38 funds tracked by Wall St. Rank hold SPRO as of Q1 2025.

  • HRT Financial reported no remaining Spero Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HRT Financial sold 14,692 Spero Therapeutics shares in Q1 2025, an estimated $15K.
  • HRT Financial first reported a position in Spero Therapeutics in Q1 2022 and held it in 3 quarters.
  • HRT Financial's Spero Therapeutics position peaked at $98K in Q1 2022.
  • 38 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.